Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry.
Moreno DF, Jiménez C, Escalante F, Askari E, Castellanos-Alonso M, Arnao M, Heredia Á, Canales MÁ, Alcalá M, Bermúdez A, Saus Carreres A, Casanova M, Palomera L, Motlló C, García-Sánchez R, Ríos Rull P, García-Sanz R, Fernández de Larrea C. Moreno DF, et al. Among authors: palomera l. Hemasphere. 2024 Nov 12;8(11):e70029. doi: 10.1002/hem3.70029. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39534383 Free PMC article.
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Lakhwani S, Mateos MV, Martínez-López J, Paiva B, Rosiñol Dachs L, Martínez R, Oriol A, Bargay J, González-Montes Y, Gironella M, Encinas C, Martín J, Jarque I, Granell M, Abella E, García-Mateo A, Hernández-Rivas JÁ, Ramila E, Krsnik I, Casado Montero LF, De Arriba F, Palomera L, Sampol A, Moraleda JM, Casanova M, Delgado P, Lafuente A, Amutio E, López-Martínez A, Altés A, Ruíz MÁ, Alegre A, Lopez-Anglada L, De La Cruz J, Alonso Fernández R, Bladé Creixenti J, Lahuerta JJ, San-Miguel J, Hernández MT. Lakhwani S, et al. Among authors: palomera l. Ann Hematol. 2024 Oct 23. doi: 10.1007/s00277-024-06031-0. Online ahead of print. Ann Hematol. 2024. PMID: 39438321
Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain.
Sancho JM, Morgades M, Alonso N, Deben G, Fernández de Sevilla A, Vázquez L, Nicolás C, García Vela JA, Arranz R, Abella E, Canales MA, Miralles P, Sánchez E, Hermosilla M, Conde E, Rueda A, Ribera JM; investigators of QUIT Study (PETHEMA, GELTAMO and GOTEL Groups). Sancho JM, et al. Med Clin (Barc). 2008 Oct 11;131(12):441-6. doi: 10.1157/13126952. Med Clin (Barc). 2008. PMID: 18928733
The bile acid chenodeoxycholic acid associates with reduced stroke in humans and mice.
Monteiro-Cardoso VF, Yeo XY, Bae HG, Mayan DC, Wehbe M, Lee S, Krishna-K K, Baek SH, Palomera LF, Wu LH, Pakkiri LS, Shanmugam S, Sem KP, Yew MG, Parsons MP, Hayden MR, Yeo LLL, Sharma VK, Drum C, Liehn EA, Sajikumar S, Davanger S, Jo DG, Chan MYY, Tan BYQ, Jung S, Singaraja RR. Monteiro-Cardoso VF, et al. Among authors: palomera lf. J Lipid Res. 2024 Nov 20:100712. doi: 10.1016/j.jlr.2024.100712. Online ahead of print. J Lipid Res. 2024. PMID: 39577772 Free article.
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabañas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosiñol L, Blade J, Cedena MT, Puig N, Paiva B; PETHEMA/GEM Cooperative Group. Lasa M, et al. Among authors: palomera l. J Clin Oncol. 2024 Oct 1:JCO2400635. doi: 10.1200/JCO.24.00635. Online ahead of print. J Clin Oncol. 2024. PMID: 39353166
Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma.
Puig N, Agullo Roca C, Sanfeliciano TC, Cedena MT, Martínez-López J, Oriol A, Blanchard MJ, Ríos-Tamayo R, Iñigo Rodríguez B, Sureda A, Lakhwani S, de la Rubia Comos J, Gonzalez-Calle V, Cabañas V, Palomera L, Moraleda JMM, Bargay J, Castro S, Rosiñol L, Bladé J, San-Miguel JF, Lahuerta JJ, Paiva B, Mateos MV. Puig N, et al. Among authors: palomera l. Blood. 2024 Sep 18:blood.2024024995. doi: 10.1182/blood.2024024995. Online ahead of print. Blood. 2024. PMID: 39293025
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Mateos MV, Martínez-López J, Rodriguez Otero P, González-Calle V, Gonzalez MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Iñigo Rodríguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, Hernández MT, Lopez Jiménez J, Reinoso-Segura M, García Mateo A, Ocio EM, Paiva B, Puig N, Cedena MT, Bladé J, Lahuerta JJ, San-Miguel JF; Spanish Myeloma Group (GEM-Pethema). Mateos MV, et al. Among authors: palomera l. J Clin Oncol. 2024 Sep 20;42(27):3247-3256. doi: 10.1200/JCO.23.02771. Epub 2024 Jul 22. J Clin Oncol. 2024. PMID: 39038268 Free PMC article.
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial.
Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV. Puig N, et al. Among authors: palomera l. Haematologica. 2024 Jul 11. doi: 10.3324/haematol.2024.285742. Online ahead of print. Haematologica. 2024. PMID: 38988266 Free article.
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Medina-Herrera A, et al. Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3. Blood Cancer J. 2024. PMID: 38684670 Free PMC article. Clinical Trial.
Dysregulation of histone deacetylases in ocular diseases.
Jun JH, Kim JS, Palomera LF, Jo DG. Jun JH, et al. Among authors: palomera lf. Arch Pharm Res. 2024 Jan;47(1):20-39. doi: 10.1007/s12272-023-01482-x. Epub 2023 Dec 27. Arch Pharm Res. 2024. PMID: 38151648 Review.
148 results